NASDAQ:ANGO - AngioDynamics Stock Price, Price Target & More

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) announced its quarterly earnings results on Wednesday, July, 11th. The medical instruments supplier reported $0.20 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.21 by $0.01. The medical instruments supplier had revenue of $88.30 million for the quarter, compared to analyst estimates of $89.02 million. AngioDynamics had a return on equity of 5.21% and a net margin of 4.74%. The company's revenue was up 1.6% on a year-over-year basis. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Wednesday, September, 26th 2018. View Earnings Estimates for AngioDynamics.

AngioDynamics updated its FY19 earnings guidance on Wednesday, July, 11th. The company provided earnings per share guidance of $0.82-0.86 for the period, compared to the Thomson Reuters consensus estimate of $0.91. The company issued revenue guidance of $344-349 million, compared to the consensus revenue estimate of $347.79 million.

6 brokers have issued 1-year target prices for AngioDynamics' shares. Their forecasts range from $16.00 to $20.00. On average, they expect AngioDynamics' share price to reach $17.4433 in the next twelve months. This suggests that the stock has a possible downside of 16.3%. View Analyst Ratings for AngioDynamics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to AngioDynamics include Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC), Nevro (NVRO), Mazor Robotics (MZOR), Glaukos (GKOS), Luminex (LMNX), Tandem Diabetes Care (TNDM), Cardiovascular Systems (CSII), Atrion (ATRI), Orthofix International (OFIX), Cryolife (CRY), AtriCure (ATRC), Intersect ENT (XENT) and OraSure Technologies (OSUR).

Media stories about ANGO stock have trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AngioDynamics earned a coverage optimism score of 0.16 on Accern's scale. They also assigned news stories about the medical instruments supplier an impact score of 46.60 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

AngioDynamics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Fenimore Asset Management Inc. (1.54%), Capital One National Association (0.36%), Bank of Montreal Can (0.15%), Boston Advisors LLC (0.12%), First National Bank of Omaha (0.09%) and Campbell & CO Investment Adviser LLC (0.06%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, David F Burgstahler, James C Clemmer and Jan Stern Reed. View Institutional Ownership Trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Fenimore Asset Management Inc. and Bank of Montreal Can. View Insider Buying and Selling for AngioDynamics.

ANGO stock was acquired by a variety of institutional investors in the last quarter, including Capital One National Association, Boston Advisors LLC, First National Bank of Omaha, Campbell & CO Investment Adviser LLC and Port Capital LLC. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer and Jan Stern Reed. View Insider Buying and Selling for AngioDynamics.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ANGO stock can currently be purchased for approximately $20.85.

AngioDynamics has a market capitalization of $766.64 million and generates $344.29 million in revenue each year. The medical instruments supplier earns $16.33 million in net income (profit) each year or $0.74 on an earnings per share basis. AngioDynamics employs 1,250 workers across the globe.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]